Cortistatin: Risks & Legal Status

Critical Safety Information#

Cortistatin is an endogenous neuropeptide that has been studied exclusively in preclinical research settings. It has never been tested in human clinical trials, and no human safety data exists. All information below is based on animal studies and pharmacological theory.

Absence of Human Data#

The most significant risk factor for cortistatin is the complete absence of human safety data:

• No phase 1 safety/tolerability studies have been conducted
• No human pharmacokinetic data exists
• No therapeutic index has been established for humans
• No dose-response relationship has been characterized in humans
• Potential for unpredicted human-specific adverse effects

Known Preclinical Risks#

Endocrine Disruption#

Cortistatin's high-affinity binding to all five somatostatin receptors creates the potential for significant endocrine effects:

• GH suppression: sst2 and sst5 activation suppresses pituitary GH release
• Insulin suppression: Pancreatic beta-cell sst receptors mediate insulin inhibition
• Glucagon suppression: Pancreatic alpha-cell sst receptors reduce glucagon output
• TSH effects: sst2 and sst5 may influence thyroid-stimulating hormone

The ghrelin receptor activation by cortistatin partially counteracts GH suppression but creates an unpredictable net hormonal effect.

Cognitive Function#

Chronic cortistatin overexpression in transgenic mice produced measurable deficits in synaptic plasticity and hippocampal learning. This suggests a narrow therapeutic window where sleep-promoting benefits must be balanced against cognitive risks.

Immune Suppression#

While cortistatin's anti-inflammatory effects are potentially therapeutic, excessive immune suppression could increase susceptibility to infections. The balance between therapeutic immunomodulation and harmful immunosuppression has not been characterized.

Regulatory Status#

Cortistatin is not regulated as a pharmaceutical in any jurisdiction. It is available as a research reagent from peptide synthesis companies.

Risk Assessment Summary#

Recommendations#

Cortistatin should be used only for in vitro and in vivo research purposes under appropriate institutional review and animal use protocols. It should not be administered to humans outside the context of properly approved clinical trials, none of which currently exist.

Risk Assessment Context#

Cortistatin belongs to the Sleep category of research peptides. Risk assessment for Cortistatin should consider both the compound-specific risks identified in clinical research and the broader regulatory environment. Researchers and healthcare providers should evaluate these risks in the context of the specific patient population and therapeutic indication.

Risk Categories#

The following risk categories have been identified for Cortistatin based on available evidence and regulatory assessments:

No Human Safety Data#

Cortistatin has never been administered to humans in clinical trials. The complete absence of human safety data means the risk profile is entirely unknown. All safety inferences are based on preclinical animal studies and theoretical pharmacological considerations.

Somatostatin-Like Hormonal Effects#

Cortistatin binds all five somatostatin receptors and may suppress growth hormone, insulin, and glucagon secretion. These endocrine effects could have significant metabolic consequences if cortistatin were administered systemically.

Cognitive Impairment Risk#

Transgenic mice overexpressing cortistatin showed deficits in synaptic plasticity and learning. Supraphysiological cortistatin levels may impair hippocampal-dependent cognitive functions.

Research-Grade Compound Risk#

Cortistatin is only available as a research-grade peptide not manufactured under GMP conditions. Research-grade products may contain impurities, endotoxins, or degradation products that pose additional safety risks.

Regulatory Status by Jurisdiction#

The regulatory and legal status of Cortistatin varies by country and jurisdiction. Researchers should verify current regulations before acquiring or using this compound.

Regulatory classifications can change. Researchers are responsible for complying with all applicable laws and regulations in their jurisdiction.

Important Warnings#

The following warnings apply to Cortistatin:

• FOR RESEARCH USE ONLY: Cortistatin has not been tested in humans and is not approved for any clinical use by any regulatory authority worldwide.
• Potential for somatostatin-like endocrine effects including suppression of growth hormone, insulin, and glucagon secretion.
• Supraphysiological levels may impair cognitive function based on transgenic mouse overexpression data.
• Short half-life and poor blood-brain barrier penetration limit the utility of native cortistatin peptide for CNS applications.
• Research-grade peptides are not manufactured to pharmaceutical standards and should not be used for human administration.

These warnings are based on available preclinical and clinical data. The absence of a warning does not indicate safety. Consult qualified professionals before making any decisions regarding peptide research.

Related Reading#

• Cortistatin overview and research guide
• Cortistatin side effects profile
• Cortistatin research evidence